Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants of 6 weeks of age (-3 to +14 days) on the date of the 1st vaccination~2. Healthy assessed from medical history and physical examination~3. Parent(s)/guardian(s) willing to let their infant follow the national Philippine childhood vaccination programme and schedule, in addition to let their infant receive the trial vaccine~4. Parent(s)/guardian(s) properly informed about the trial and has signed the informed consent form~5. Parent(s)/guardian(s) granting access to the infant's trial related medical records~6. Parent(s)/guardian(s) likely to comply with the trial procedures~Exclusion Criteria:~1. Vaccinated with any polio vaccine other than the trial vaccines, prior to inclusion or planned during the trial~2. OPV vaccination or known exposure to poliovirus (wild or vaccine derived) in household (living together) within 3 months prior to inclusion or planned during the trial~3. Low birth weight (\< 2,500 g)~4. Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criteria~5. Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease~6. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)~7. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~8. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial~9. Participating in another clinical trial~10. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 9 Months
- Healthy Volunteers: t

Study Arms:
- IPV-Al SSI (Type: EXPERIMENTAL): IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
- IPV SSI (Type: ACTIVE_COMPARATOR): IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).